PhRMA
950 F Street, NW
Washington
D.C.
20004
Tel: 202-835-3400
Fax: 202-835-3414
Website: http://www.phrma.org/
About PhRMA
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading research-based pharmaceutical and biotechnology companies, which are devoted to inventing medicines that allow patients to live longer, healthier, and more productive lives. The industry invested more than $30 billion in 2001 in discovering and developing new medicines. PhRMA companies are leading the way in the search for new cures.For more information, visit PhRMA's Home Page at www.phrma.org.
92 articles with PhRMA
-
The Inflation Reduction Act, which is expected to have wide-ranging implications for the pharmaceutical industry, will still need to go to the House of Representatives.
-
CMS says it would only cover the cost of Biogen’s Aduhelm and any required scans “if they are enrolled in qualifying clinical trials.”
-
As the number of diagnosed cases of COVID-19 continue to increase across the globe and more and more governments are urging citizens to self-quarantine, the pharmaceutical and life sciences industry continues to work toward the development of a vaccine and therapies for the respiratory infection ...
-
One of the criticisms of the biopharma industry—at least in the context of drug pricing—is how much the industry as a whole spends on lobbyists. For example, last year, PhRMA, the industry lobbying group, spent more than $27.5 million on its lobbying activities.
-
When biotech companies post openings for new positions, hiring managers often face the immense task of sorting through numerous resumes of qualified candidates. However, in South Korea, hiring managers are facing a different problem – a dearth of qualified candidates.
-
After Health and Human Services Secretary Alex Azar, a former executive with Eli Lilly, unveiled a pricing reform that would allow pharma companies to end the rebate system and pass those savings directly to consumers, leaders from across the pharma industry are offering early support for the pro...
-
Last week HHS floated a plan that would allow companies to pass rebates of 26 to 30 percent of a drug’s list price directly to patients in order to be reflected in what consumers pay at the pharmacy counter.
-
Recently, in the U.S., there has been a shortage of an anti-anxiety drug, buspirone. The American Society of Health-System Pharmacists (ASHP) lists shortages, and as of Jan. 31, 2019, noted shortages of buspirone tablets manufactured by Accord Healthcare, Mylan and Teva Pharmaceutical.
-
The U.S. Senate Finance Committee and the House Oversight Committee started hearings on Tuesday, January 29, focused on dealing with high drug prices.
-
It’s no secret that the pharmaceutical industry spends a significant amount of money lobbying state and federal governments to gain leverage that will benefit individual companies and the industry overall.
-
U.S. federal lawmakers are discussing various legislative plans that could lower the out-of-pocket expenses many Americans pay for their medications. The plans are coming from both chambers of Congress and with a divided government, lines in the sand will likely be drawn.
-
This morning the Pharmaceutical Research and Manufacturers of America (PhRMA) released a report that shows there are nearly 300 novel cell and gene therapies currently in development throughout the industry. The therapies are being studied as treatments for a variety of diseases and conditions.
-
Noting that from 1998 to 2017 there have been about 146 failed shots at developing drugs for Alzheimer’s disease, PhRMA released a report on the state of the industry. This would not lead most people to think there are many reasons to be optimistic about Alzheimer’s disease research, but the repo...
-
While many consider failure to be a completely negative experience, that’s not always the case, as every failure is still a lesson learned. Occasionally, these failures can even lead to some of the biggest breakthroughs in medical history.
-
“President Trump is taking historic action to bring patients more transparency through consumer advertising,” Azar said in a speech. “We are proposing to require American drug companies for the first time ever to include in their TV advertising the list prices of drugs paid for by Medicare or Med...
-
As federal lawmakers continue to wrangle over legislation to help curb the opioid crisis in the United States, the House of Representatives is showing some division over the costs that some pharmaceutical companies may have to pay for Medicare coverage.
-
With $500K, PhRMA Joins ‘Billionaire Boys Club’ of Corporate Landlords Against Prop. 10 and Protections for Renters
9/20/2018
The Pharmaceutical Research and Manufacturers Association (PhRMA), the drug industry’s trade group and lobbying arm, donated $500,000 to the ‘No on 10’ campaign, joining with greedy billionaire corporate landlords to oppose Prop. 10, a November ballot measure that will empower communities to limit rent increases and address California’s housing affordability crisis.
-
As President Donald Trump attempts to revise the North American Free Trade Agreement (NAFTA) between the U.S., Mexico and Canada, generic drugmakers have expressed concern over some of the negotiating points.
-
U.S. Senate Spending Bill Calls for TV Ad Price Disclosure of Drugs, Increases Spending on Alzhei...
8/24/2018
A spending bill passed in the U.S. Senate includes provisions taking aim at the high cost of prescription medicines by requiring pharmaceutical companies to disclose the cost of medications in television advertisements. -
The industry group PhRMA released its 2018 PhRMA member annual survey along with the 2018 Biopharmaceutical Research Industry Profile. Among the findings was that overall research-and-development spending was at an all-time high in 2017, hitting $71.4 billion, up from $65.5 billion in 2016 and fr...